These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 12678254)

  • 1. Validation of an in vitro potency test for the Cuban hepatitis B vaccine.
    Landys Chovel Cuervo M; Reyes Huerta N
    Dev Biol (Basel); 2002; 111():305-12. PubMed ID: 12678254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between in vitro potency tests for Cuban hepatitis B vaccine: contribution to the standardization process.
    Cuervo ML; de Castro Yanes AF
    Biologicals; 2004 Dec; 32(4):171-6. PubMed ID: 15572098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro versus in vivo concordance: a case study of the replacement of an animal potency test with an immunochemical assay.
    Schofield T
    Dev Biol (Basel); 2002; 111():299-304. PubMed ID: 12678253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment and validation of an ELISA for the quantitation of HBsAg in recombinant hepatitis B vaccines.
    Costa CI; Delgado IF; da Costa JA; de Carvalho RF; Mouta Sda S; Vianna CO; de Moraes MT
    J Virol Methods; 2011 Mar; 172(1-2):32-7. PubMed ID: 21185330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of a new alternative for determining in vitro potency in vaccines containing Hepatitis B from two different manufacturers.
    Cuervo ML; Sterling AL; Nicot IA; Rodríguez MG; García OR
    Biologicals; 2008 Nov; 36(6):375-82. PubMed ID: 18693036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of an in-vitro method for Hepatitis B vaccine potency assay: specification setting.
    Karimzadeh H; Ajdary S; Jazayeri SM; Pakzad SR
    Panminerva Med; 2010 Sep; 52(3):177-82. PubMed ID: 21045773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Replacement, reduction and refinement alternatives to animal use in vaccine potency measurement.
    Hendriksen CF
    Expert Rev Vaccines; 2009 Mar; 8(3):313-22. PubMed ID: 19249973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Release potency tests of hepatitis vaccines.
    Descamps J; Mary A; Rommel E; Anhoury ML; De Neys R; Duchêne M
    Dev Biol Stand; 1999; 101():289-94. PubMed ID: 10566803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro potency assay for hepatitis A vaccines: development of a unique economical test.
    Poirier B; Morgeaux S; Variot P; Fuchs F
    Biologicals; 2000 Dec; 28(4):247-56. PubMed ID: 11237361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Selecting methods of controls concentration for internal quality control and continuity of control chart between different reagent lots for HBsAg qualitative detection].
    Li JM; Zheng HJ; Wang LN; Deng W
    Zhonghua Gan Zang Bing Za Zhi; 2003 Apr; 11(4):228-31. PubMed ID: 12716523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of a new ELISA method for in vitro potency assay of hepatitis B-containing vaccines.
    Giffroy D; Mazy C; Duchêne M
    Pharmeuropa Bio; 2006 Nov; 2006(1):7-14. PubMed ID: 17270127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Would an in vitro ELISA test be a suitable alternative potency method to the in vivo immunogenicity assay commonly used in the context of international Hepatitis A vaccines batch release?
    Poirier B; Variot P; Delourme P; Maurin J; Morgeaux S
    Vaccine; 2010 Feb; 28(7):1796-802. PubMed ID: 20018270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety assessment of the Cuban recombinant hepatitis B vaccine in healthy adults.
    Estévez ZC; Betancourt AA; Muzio González V; Baile NF; Silva CV; Bernal FH; Arias EP; Delhanty Fernández A; Olazábal NM; del Río Martín A; Batista LL; Véliz Ríos G; Hernández HH; Hernández AB; Lugo EP; de la Torre Cruz J; Batista Marchec BL; Falcón LA; Brito JT; León DO; Saura PL
    Biologicals; 2007 Apr; 35(2):115-22. PubMed ID: 17056272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Surveillance in children of mothers positive to hepatitis B surface antigen, 2000-2002].
    Bello Corredor M; Rodriguez Lay Lde L; Delgado González G; Diaz González M; Montalvo Villar MC; Gutiérrez Moreno A
    Rev Cubana Med Trop; 2004; 56(1):31-4. PubMed ID: 15849906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ensuring quality of in vitro alternative test methods: Current practice.
    Rispin A; Stitzel K; Harbell J; Klausner M
    Regul Toxicol Pharmacol; 2006 Jul; 45(2):97-103. PubMed ID: 16644076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cellular immune responses of recombinant hepatitis B (rHB) vaccine and HBsAG derived from Hansenula polymorpha cells].
    Hu ZY; He P; Zhang R; Fang X; Zhu FC; Qiu SH; Li HM; Wang H; Liang ZL; Zhuang H
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jul; 29(7):706-11. PubMed ID: 19031766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of HBsAg mutants and impact of hepatitis B infant immunisation in four Pacific Island countries.
    Basuni AA; Butterworth L; Cooksley G; Locarnini S; Carman WF
    Vaccine; 2004 Jul; 22(21-22):2791-9. PubMed ID: 15246613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Enhancement of a hepatitis B DNA vaccine potency using aluminum phosphate in mice].
    Liang ZW; Ren H; Lang YH; Li YG
    Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):79-81. PubMed ID: 14980105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal design and validation of antiviral siRNA for targeting hepatitis B virus.
    Fu J; Tang ZM; Gao X; Zhao F; Zhong H; Wen MR; Sun X; Song HF; Qian XH
    Acta Pharmacol Sin; 2008 Dec; 29(12):1522-8. PubMed ID: 19026173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serological methods for potency testing of tetanus toxoid vaccines for human use.
    Hendriksen C; Winsnes R
    Dev Biol (Basel); 2002; 111():131-40. PubMed ID: 12678232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.